% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{GrobeEinsler:283018,
author = {Grobe-Einsler, Marcus and Borel, Stéphanie and Buchholz,
Maresa and Sayah, Sabrina and Hilab, Rania and Pierron,
Lucie and Iskandar, Audrey and Humphries, Brittany and
Ewenczyk, Claire and Heinzmann, Anna and Atencio, Mariana
and Feldmann, Katrin and Maas, Vivian and Faber, Jennifer
and Boesch, Sylvia and Indelicato, Elisabetta and Reetz,
Kathrin and Schulz, Jörg B. and Bischoff, Almut T. and
Klopstock, Thomas and Schöls, Ludger and Minnerop, Martina
and Timmann, Dagmar and Davies, Elin H. and Klockgether,
Thomas and Durr, Alexandra and Xie, Feng and Michalowsky,
Bernhard},
title = {{P}atient-reported, psychosocial and health economic
outcomes in mild to moderate {F}riedreich's ataxia: baseline
results of the {PROFA} study},
journal = {The lancet / Regional health. Europe},
volume = {61},
issn = {2666-7762},
address = {[Amsterdam]},
publisher = {Elsevier},
reportid = {DZNE-2025-01430},
pages = {101552},
year = {2026},
note = {Funding: European Joint Programme on Rare Diseases (EJP
RD).},
abstract = {Background: Friedreich ataxia (FA) is the most common
autosomal recessive ataxia. Little attention has been paid
to FA's impact on patient-reported, psychosocial, and
health-economic outcomes. This study aimed to report these
outcomes across FA's disability stages 1–5. Methods: We
assessed patients in Germany, France, and Austria as part of
the PROFA study, a European multicenter observational study.
The protocol included a study center visit followed by a
remote mobile assessment capturing ataxia severity (SARA),
daily living deficits (FARS-ADL), cognitive and affective
impairments (CCAS), health-related quality of life (HRQoL:
PROM-Ataxia short-form, EQ-5D-5L), mental well-being
(WEMWBS), communication disabilities (COMATAX), and
healthcare and informal care utilization. FARS disability
stages were used to demonstrate outcomes with effect size
measures (Eta-Squared, Cramér's V). Multivariate regression
models evaluated associations between z-standardized
outcomes and disability stages. Findings: One hundred one
patients (mean [SD]: age 35.0 [11.5]; GAA-repeat size 657
[299]; $50.5\%$ women) were included. Activities of daily
living, HRQoL, communication disabilities, and informal care
utilization worsened significantly across disability stages
with moderate to high effect sizes. Cognitive-affective
impairments and mental well-being showed significant
associations with small effect sizes. Twenty-three patients
$(33.3\%)$ received formal care, while 40 $(58.0\%)$
received informal care (mean 12.2 h/week). Omaveloxolone was
used by 33 patients $(32.7\%).$ Annual healthcare costs
excluding Omaveloxolone were €13,620 (payer) and €32,679
(societal perspective, including informal care and
productivity losses). Interpretation: The results emphasize
the multidimensional patient, societal, and economic burden
of FA and the need for comprehensive care addressing
physical, mental, and psychosocial health.},
cin = {AG Michalowsky / Clinical Research (Bonn) / AG Thyrian / AG
Hoffmann / AG Spottke / Clinical Research (Munich) / AG
Schöls / Patient Studies (Bonn)},
ddc = {610},
cid = {I:(DE-2719)5000067 / I:(DE-2719)1011001 /
I:(DE-2719)1510800 / I:(DE-2719)1510600 / I:(DE-2719)1011103
/ I:(DE-2719)1111015 / I:(DE-2719)5000005 /
I:(DE-2719)1011101},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
doi = {10.1016/j.lanepe.2025.101552},
url = {https://pub.dzne.de/record/283018},
}